| Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis |
Recruiting |
Rheumatoid Arthritis |
NCT04871919 |
| An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. |
Terminated |
Psoriatic Arthritis |
NCT03320876 |
| A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis |
Completed |
Ankylosing Spondylitis |
NCT03117270 |
| Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients |
Active, not recruiting |
Rheumatoid Arthritis |
NCT02065700 |
| Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH) |
Recruiting |
Rheumatoid Arthritis |
NCT04985435 |
| Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function |
Completed |
Rheumatoid Arthritis |
NCT03417778 |
| Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease |
Enrolling by invitation |
Crohn's Disease |
NCT02914600 |
| Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis |
Active, not recruiting |
Ulcerative Colitis |
NCT02914535 |
| Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease |
Completed |
Fistulizing Crohn's Disease |
NCT03077412 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) |
Completed |
Small Bowel Crohn's Disease |
NCT03046056 |
| Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis |
Terminated |
Noninfectious Uveitis |
NCT03207815 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy |
Withdrawn |
Ankylosing Spondylitis |
NCT04483700 |
| Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease |
Active, not recruiting |
Crohn's Disease |
NCT02914561 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy |
Withdrawn |
Ankylosing Spondylitis |
NCT04483687 |
| Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis |
Active, not recruiting |
Rheumatoid Arthritis |
NCT03025308 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy |
Terminated |
Psoriatic Arthritis |
NCT04115839 |
| Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate |
Recruiting |
Rheumatoid Arthritis|JAK Inhibitor|IL-6 Inhibitor|Musculoskeletal Ultrasound|Biomarker |
NCT05090410 |
| Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment |
Completed |
Rheumatoid Arthritis |
NCT02873936 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis |
Completed |
Ulcerative Colitis |
NCT02914522 |
| A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis |
Completed |
Psoriatic Arthritis |
NCT03101670 |
| Oral Bioavailability of Two Solid Formulations of GLPG0634 |
Completed |
Healthy |
NCT01915667 |
| Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy |
Completed |
Rheumatoid Arthritis |
NCT02886728 |
| A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects |
Completed |
Healthy |
NCT01798979 |
| Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease |
Completed |
Crohn's Disease |
NCT02048618 |
| Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) |
Completed |
Lupus Membranous Nephropathy |
NCT03285711 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy |
Terminated |
Psoriatic Arthritis |
NCT04115748 |
| Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects |
Completed |
Healthy |
NCT01820806 |
| Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects |
Completed |
Healthy |
NCT02162355 |
| Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants |
Completed |
Rheumatoid Arthritis |
NCT04608344 |
| Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis |
Active, not recruiting |
Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Non-Radiographical Axial Spondyloarthritis |
NCT03926195 |
| Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) |
Completed |
Cutaneous Lupus Erythematosus |
NCT03134222 |
| Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects |
Completed |
Renal Impairment |
NCT02084199 |
| Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate |
Completed |
Rheumatoid Arthritis |
NCT02889796 |
| Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects |
Completed |
Healthy |
NCT01665924 |
| Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome |
Completed |
Sjogren's Syndrome |
NCT03100942 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects |
Completed |
Healthy |
NCT01419990 |
| Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease |
Active, not recruiting |
Inflammatory Bowel Disease |
NCT03201445 |
| Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2) |
Completed |
Rheumatoid Arthritis |
NCT01894516 |
| Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients |
Completed |
Rheumatoid Arthritis |
NCT01668641 |
| Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1) |
Completed |
Rheumatoid Arthritis |
NCT01888874 |
| Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients |
Completed |
Rheumatoid Arthritis |
NCT01384422 |
| First-in-Human Single Ascending and Multiple Dose of GLPG0634 |
Completed |
Healthy |
NCT01179581 |
| Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate |
Completed |
Rheumatoid Arthritis |
NCT02885181 |
| Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis |
Not yet recruiting |
Rheumatoid Arthritis |
NCT05119452 |
| A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients |
Completed |
Sjogren's Syndrome |
NCT04916756 |
